Teva Pharmaceutical Industries TEVA
NYSE TEVA
$39.52 -0.54 (-1.35%)
As of: Sep 22, 2026 · 3:59 PM EDT

Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity (2009 - 2026)

Teva Pharmaceutical Industries' (TEVA) quarterly Liabilities and Shareholders Equity came in at $39.9 billion in Q2 2026, down 0.68% on a YoY basis from $40.1 billion in Q2 2025, and little changed quarter-over-quarter from $40.0 billion in Q1 2026.

Analysis

Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVA) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $39.9 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 0.68% year-over-year to $39.9 billion; the trailing twelve-month figure through Jun 2026 stood at $160.5 billion (up 0.55% YoY), and the FY2025 full-year result was $40.7 billion, up 3.62% from the prior year.
  • Liabilities and Shareholders Equity held at $39.9 billion in Q2 2026 per TEVA's latest filing, from $40.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $47.1 billion in Q1 2022 and bottomed at $38.4 billion in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $42.1 billion across 5 years, with a median of $41.9 billion in 2023.
  • The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity retreated 10.19% in 2025, then grew 4.23% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then gained by 3.62% to $40.7 billion in 2025, then dropped by 2.19% to $39.9 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $39.9 billion, $40.0 billion, and $40.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Teva Pharmaceutical Industries 46.72 Bn 43.07 Bn 2.15 Bn 39.86 Bn
2 Viatris 19.64 Bn 18.75 Bn 1.46 Bn 35.04 Bn
3 Dr Reddys Laboratories 10.36 Bn 10.22 Bn 396.53 Mn 6.08 Bn
4 Amneal Pharmaceuticals 6.44 Bn 6.39 Bn 334.51 Mn 3.78 Bn
5 Bausch Health Companies 2.11 Bn 1.24 Bn 2.10 Bn 24.79 Bn
6 Ani Pharmaceuticals 1.88 Bn 1.52 Bn 165.89 Mn 1.49 Bn
7 Alvotech 1.83 Bn 1.69 Bn 2.56 Mn 1.59 Bn
8 Amphastar Pharmaceuticals 1.04 Bn 751.07 Mn 93.47 Mn 1.74 Bn
9 Fennec Pharmaceuticals 382.22 Mn 340.97 Mn 17.15 Mn 75.75 Mn
10 NutriBand 94.45 Mn 91.03 Mn 181,874.00 6.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 39.86 Bn
Mar 31, 2026 40.04 Bn
Dec 31, 2025 40.75 Bn
Sep 30, 2025 39.86 Bn
Jun 30, 2025 40.13 Bn
Mar 31, 2025 38.42 Bn
Dec 31, 2024 39.33 Bn
Sep 30, 2024 41.76 Bn
Jun 30, 2024 41.34 Bn
Mar 31, 2024 42.77 Bn
Dec 31, 2023 43.48 Bn
Sep 30, 2023 42.10 Bn
Jun 30, 2023 43.10 Bn
Mar 31, 2023 43.46 Bn
Dec 31, 2022 44.01 Bn
Sep 30, 2022 44.25 Bn
Jun 30, 2022 45.93 Bn
Mar 31, 2022 47.06 Bn
Dec 31, 2021 47.67 Bn
Sep 30, 2021 47.85 Bn
API Access

Teva Pharmaceutical Industries Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=TEVA&period=max&api_key=YOUR_API_KEY